Worsening Heart Failure on Maximal Triple Therapy

Add an SGLT2 inhibitor (dapagliflozin or empagliflozin). In HFrEF, this class reduces cardiovascular death and heart failure hospitalization within weeks and works independently of diabetes status and of the other neurohormonal agents. It remains effective at his eGFR (roughly 38), so renal function is not a barrier at this level.

The judgment call is what to fix first:

• Potassium 5.2 on an MRA. Adding another agent that raises potassium (or simply ignoring the value) risks hyperkalemia. Reduce or hold eplerenone, review dietary potassium, salt substitutes, NSAIDs, and any trimethoprim or potassium supplements, and recheck a basic metabolic panel within 1–2 weeks. SGLT2 inhibitors actually lower potassium modestly, so they are not the problem here - but the MRA is.
• Orthostatic symptoms with a narrow pulse pressure argue against indiscriminate intensification; he is mildly congested (JVP 10, 1.6 kg gain) but not overloaded, so treat congestion gently rather than aggressively.
• Do not stop carvedilol or sacubitril/valsartan - both are more valuable long term than the transient blood pressure concern suggests.

He sits at the difficult intersection of mild residual congestion and symptomatic orthostasis. Increase cautiously; do not do nothing, and do not push hard.

Evidence for congestion: JVP 10 cm with hepatojugular reflux, bibasilar crackles, 1+ edema, 1.6 kg gain in eight days.

Evidence against aggressive diuresis: supine hypotension with a further drop on standing, narrow pulse pressure, and creatinine already above baseline. A 15–20 mmHg orthostatic drop with symptoms usually reflects either intravascular depletion or low cardiac output - and in a patient with an EF of 28%, low output is a real possibility.

Practical approach:

• Check orthostatic vitals and look for other causes of dizziness (carvedilol timing, hypovolemia from poor intake, anemia).
• If he is truly congested, a modest increase (e.g., 40 mg to 60 mg daily or a short course of added metolazone-free escalation) with daily weights and a repeat BMP in 5–7 days is reasonable. Aim for a gentle net negative balance rather than rapid decongestion.
• Reassess whether his estimated dry weight is too low. If he becomes symptomatically hypotensive or creatinine climbs steeply, back off and reconsider the target weight rather than adding pressors or inotropes.

Monitoring

• Basic metabolic panel (potassium, creatinine, bicarbonate) in 1–2 weeks after any change, then per usual care.
• Daily weights at home with a written threshold for calling (e.g., >2 kg in 3 days).
• Blood pressure log, including standing readings.

Counseling

• Sick-day rules: hold the SGLT2 inhibitor (and consider holding the diuretic and RAAS inhibitor) during acute illness with vomiting, poor oral intake, or dehydration. This is the single highest-yield instruction, because it prevents the two most feared complications - volume-depletion prerenal injury and euglycemic diabetic ketoacidosis, which can occur with normal or only modestly elevated glucose and is easily missed.
• Genital mycotic infections and, less commonly, urinary tract infections; hygiene counseling.
• Do not use potassium-containing salt substitutes.
• Avoid NSAIDs.
• Continue the SGLT2 inhibitor before procedures unless instructed otherwise by the procedural team.

Why the emphasis on euglycemic DKA: a patient with heart failure and an EF of 28% who presents nauseated and volume-depleted may have ketoacidosis with a glucose of 180 mg/dL; if nobody checks ketones, the diagnosis is delayed. Name it explicitly in the after-visit instructions.